RBL LLC welcomes James Watson to board of directors
Txylo.com/10312852
Trending...
- Desiray Clarkson Joins Special Minds Unlocked as Board Advisor for Special Education Strategy
- "Martin" Star Bruh Man and R&B Star Alisa Peoples-Yarbrough Join "Mother of Inmates" — Featured on FOX 4 News
- Surplus Buyers & Demo Partners With Demolition Companies
HOUSTON, June 17, 2025 ~ Houston, TX - RBL LLC, a biotech venture creation studio focused on developing groundbreaking medical technologies from Rice University, has announced the addition of James Watson to its board of directors. Watson, an operating partner at Andreessen Horowitz and a seasoned executive in the life sciences industry, brings a wealth of experience in business strategy, corporate development, and venture-backed company building to RBL LLC.
According to Paul Wotton, managing partner at RBL LLC, the appointment of James Watson is a strong endorsement of the company's model and potential. With his extensive background in all stages of biotech innovation, from company formation to valuable partnerships, Watson's insights into market dynamics and ability to drive successful outcomes will be crucial as RBL continues to grow.
Rice professor of bioengineering and managing partner of RBL LLC, Omid Veiseh also expressed his excitement about Watson joining the board. He believes that Watson's ability to bridge science and business, along with his track record in corporate development, aligns perfectly with RBL's mission to translate Rice University's biomedical breakthroughs into high-impact startups.
More on Txylo.com
In response to his appointment, James Watson stated that he was drawn to RBL's innovative approach to company creation and its positive impact on the Houston life sciences community. He praised the studio for its efficient approach in identifying promising technologies with clear clinical applications and establishing focused enterprises to advance them. He also highlighted the strategic positioning of RBL in Houston as a key factor in building successful scientific ventures.
Currently serving as an operating partner on the Bio + Health team at Andreessen Horowitz, Watson leads business and corporate development for the firm's life sciences portfolio. Prior to this role, he held executive positions at several biotech companies including Carmot Therapeutics and Sigilon Therapeutics. At Carmot Therapeutics, he led the raising of over $200 million for the company's pipeline and discovery platform and built business development relationships that contributed to its $2.7 billion acquisition by Roche. He also served as chief business officer and president ICT at Sigilon Therapeutics, where he led a $485 million cell therapies partnership with Lilly.
With an MBA from Indiana University and a bachelor's degree in economics from the University of Portsmouth, Watson brings a strong educational background to the RBL board.
Watson will join existing board members Wotton, Veiseh, Rima Chakrabarti, John Jaggers, Devyn Smith, and Paul Cherukuri. This accomplished group of leaders with deep expertise in biotech innovation, clinical translation, and venture building will provide strategic guidance to help drive RBL's continued growth and success.
According to Paul Wotton, managing partner at RBL LLC, the appointment of James Watson is a strong endorsement of the company's model and potential. With his extensive background in all stages of biotech innovation, from company formation to valuable partnerships, Watson's insights into market dynamics and ability to drive successful outcomes will be crucial as RBL continues to grow.
Rice professor of bioengineering and managing partner of RBL LLC, Omid Veiseh also expressed his excitement about Watson joining the board. He believes that Watson's ability to bridge science and business, along with his track record in corporate development, aligns perfectly with RBL's mission to translate Rice University's biomedical breakthroughs into high-impact startups.
More on Txylo.com
- They Split the Brick. OG Mack Drama Kept the Foundation
- Rodeo City Provisions Elevates Texas BBQ, Catering, and Private Events in Dallas-Fort Worth
- Surplus Buyers & Demo Now Buying Decommissioned Fleet Vehicles, Forklifts and Plant Equipment
- Ella Langley Hits the 2026 CMA Awards Red Carpet in Custom KmXtend Clip-In Extensions Styled by Chris Bear
- Aquvi313 Launches Daily Calming Mist, a Hypochlorous Acid Facial Mist Made for Tween Skin
In response to his appointment, James Watson stated that he was drawn to RBL's innovative approach to company creation and its positive impact on the Houston life sciences community. He praised the studio for its efficient approach in identifying promising technologies with clear clinical applications and establishing focused enterprises to advance them. He also highlighted the strategic positioning of RBL in Houston as a key factor in building successful scientific ventures.
Currently serving as an operating partner on the Bio + Health team at Andreessen Horowitz, Watson leads business and corporate development for the firm's life sciences portfolio. Prior to this role, he held executive positions at several biotech companies including Carmot Therapeutics and Sigilon Therapeutics. At Carmot Therapeutics, he led the raising of over $200 million for the company's pipeline and discovery platform and built business development relationships that contributed to its $2.7 billion acquisition by Roche. He also served as chief business officer and president ICT at Sigilon Therapeutics, where he led a $485 million cell therapies partnership with Lilly.
With an MBA from Indiana University and a bachelor's degree in economics from the University of Portsmouth, Watson brings a strong educational background to the RBL board.
Watson will join existing board members Wotton, Veiseh, Rima Chakrabarti, John Jaggers, Devyn Smith, and Paul Cherukuri. This accomplished group of leaders with deep expertise in biotech innovation, clinical translation, and venture building will provide strategic guidance to help drive RBL's continued growth and success.
Filed Under: Business
0 Comments
Latest on Txylo.com
- Calorie Tracker App DietApp.com Helps Track Holiday Meals With AI Calorie Scanner and GLP1 Tracker
- NANNNA Shines in Stamford: The Men Who Came to Support Their Wives
- Aoolia Offers Free Virtual Try On Glasses for 1,500+ Frames Using Just a Phone Camera
- Design Estimation Offers 25% Off for New Clients and 20% Off for Existing Clients Through Nov. 27
- On the Rocks Italian Bistro Serves Thanksgiving Dinner in Old Town Burleson
- Education Through Music-LA Honors Grammy-Winning Pitch Perfect Music Supervisors Julianne Jordan & Julia Michels, Educator Anthony "Tony" White
- Peptide Price Lab Names Its November Top 10 Peptide Vendors, and No Vendor Can Pay for a Place
- TOKSTAR Welcomes NBA 2K Star Young Wayne
- The Dallas Way Celebrates 2026 at Winter Brunch
- Matt Zavala of Zavala Law, PC Elected to Ventura County Bar Association Board of Directors
- Fed Rate Hike Expected in December: What Austin Home Buyers Can Do Now, Says Sarah Maddali
- Montana Artist Ryan Jolley Receives Goodman Award at Mountain Oyster Club Art Show
- Fredericksburg Luxury and Short-Term Rental REALTOR Savannah Sikes Surpasses $115 Million in Sales
- Make Your Move to Luxury Living at Heritage at Hopewell with Rates Starting at Just 3.750% (5.803% APR)
- Scott Glickson Joins STS Capital Partners as Managing Director
- BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy
- Classic Country TV Releases George Jones Archive, Complete Country History After KWTX Feature
- GLP1 Tracker App DietApp.com Lets Ozempic, Wegovy, Mounjaro and Zepbound Users Log Each Dose
- Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Dallas–Fort Worth
- It's Not Property — It's Money: Texas Lone Star Recovery Group Explains Unclaimed Property